Establishing Fibroblast-Derived Cell Lines From Skin Biopsies of Patients With Immunodeficiency or Immunodysregulation Disorders
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Background:
- National Institutes of Health (NIH) researchers have been studying immune cells (white blood cells) to better understand how the human body s defense system works and adjusts or regulates itself, and how changes in this system can make a person sick.
- To study the cells of patients who have problems with their immune systems, researchers would like to collect samples of skin cells from patients with immune system disorders and compare them with skin cells taken from healthy volunteers. By studying these cells, researchers hope to determine whether these cells can be modified to create a new kind of personalized gene therapy that would attempt to cure immune diseases in the future.
Objectives:
- To obtain skin cells from patients with immune system disorders and from healthy volunteers for research and comparison purposes.
Eligibility:
- Patients between the ages of 2 and 85 who have immune system disorders.
- Healthy volunteers between the ages of 18 and 85.
- Both groups will be selected from the eligible participants of existing NIH studies into immune system disorders.
Design:
- Researchers may take up to two biopsies from participants arms, legs, abdomen, or back.
- The biopsy site will be numbed with local anesthetic and cleaned before the sample is taken.
- The punch skin biopsy needle will be inserted into the skin and rotated to remove a small circle of skin (approximately 1/4 to 3/8 of an inch across). The area will be closed with bandages or stitches, and then covered with a dressing. Any stitches will be removed in 7 to 10 days.
- Tissue samples collected in the study will be stored for future research.
| Condition |
|---|
|
Lymphohistiocytosis, Hemophagocytic Common Variable Immunodeficiency Severe Combined Immunodeficiency |
| Study Type: | Observational |
| Study Design: | Time Perspective: Prospective |
| Official Title: | Establishing Fibroblast-derived Cell Lines From Skin Biopsies of Patients With Immunodeficiency or Immunodysregulation Disorders |
- We plan to obtain skin punch biopsies to generate fibroblast, dermal, or other skin-resident cell lines in patients who previously underwent HSCT. Cells may also be used for somatic cell hybridization, cell complementation, assessing fibroblast-... [ Time Frame: Over the lifetime of the study ] [ Designated as safety issue: No ]
- A second objective of this study is to generate induced pluripotent stem cells (iPS) from skin cells of patients or healthy volunteers, serving as controls. [ Time Frame: Over the lifetime of the study ] [ Designated as safety issue: No ]
| Enrollment: | 59 |
| Study Start Date: | May 2009 |
This protocol is designed as an adjunct to other NIAID IRB approved protocols that allow for genetic testing, which may include those that are screening protocols for patients with rare primary inmmnodeficiency or immunodysregulation disorders. Patients deemed of sufficient research interest after review of outside medical records, clinical evaluation, and testing may be invited to participate in this study. Healthy volunteers will also be invited to participate as a source of control samples for research testing. After consent and enrollment into this study, skin punch biopsies will be obtained to establish dermal fibroblast cell lines for research studies directed at understanding the genetic and biochemical bases of these diseases. Cell lines will also be used to investigate the utility of induced pluripotent stem cells (iPS) for lymphocyte derivation and targeted gene correction. Results with the potential to impact medical care will be relayed to the referring physicians and where applicable, patients will be referred to other appropriate NIH protocols for additional clinical evaluation and treatment. The study will enroll up to 200 patients and healthy volunteers over the next 5 years.
Eligibility| Ages Eligible for Study: | 2 Years to 85 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
- INCLUSION CRITERIA:
Patients:
To be enrolled in this study, a patient must be greater than or equal to 2 years of age but not greater than 85 years of age, have a known diagnosis of primary immunodeficiency or immunodysregulation (or be a blood relative of such as patient), and be concurrently enrolled on an NIAID IRB approved protocol that includes genetic testing for disease of the immune system, such as but not limited to 05-I-0213 or 06-I-0015.
Healthy Volunteers:
To be enrolled in this study, a normal volunteer must fulfill all of the following criteria:
- 1. Be enrolled on protocol 05-I-0213.
- 2. Be a healthy adult of either sex and between ages of 18 years and 85 years
EXCLUSION CRITERIA:
Patients with a primary immunodeficiency or immunodysregulation disorder (or a blood relative of such a patient) are not eligible to be in this trial if:
- 1. Platelet count less than 20,000/microL
- 2. Patient is hemodynamically unstable because of acute bleeding.
- 3. Any condition that, in the investigator s opinion, places the patient at undue risk by participating in the study or limits the utility of the specimen to be obtained.
A Healthy Volunteer is not eligible to be in this trial if he or she fulfills any of the following criteria:
- 1. Less than 18 years old or older than 85 years
- 2. Weighs less than 110 pounds
- 3. Is pregnant or breastfeeding
- 4. Is receiving a chemotherapeutic agent(s) or has a malignancy
- 5. Cannot avoid taking aspirin or non-steroidal anti-inflammatory medications during the 7 days preceding skin biopsy
- 6. Have history of heart, lung, kidney disease, bleeding disorders, diabetes mellitus, chronic peripheral arterial or venous insufficiency, chronic diffuse skin conditions without uninvolved areas suitable for skin biopsy, poor skin healing, or keloid formation.
- 7. Has been diagnosed as having viral hepatitis (B or C), human immunodeficiency virus (HIV), or a carrier for methicillin-resistant Staphylococcus aureus (MRSA)
- 8. Hemoglobin measurement is less than 12.0 g/dL
- 9. Platelet count less than 150,000/(micro)L
- 10. PT greater than 15.0 seconds or PTT greater than 40 seconds
- 11. Has a history of intravenous injection drug use or of engaging in high-risk activities for exposure to the acquired immunodeficiency syndrome (AIDS) virus.
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT00895271
| United States, Maryland | |
| National Institutes of Health Clinical Center, 9000 Rockville Pike | |
| Bethesda, Maryland, United States, 20892 | |
| Principal Investigator: | Helen C Su, M.D. | National Institute of Allergy and Infectious Diseases (NIAID) |
More Information
Additional Information:
Publications:
| Responsible Party: | National Institutes of Health Clinical Center (CC) ( National Institute of Allergy and Infectious Diseases (NIAID) ) |
| ClinicalTrials.gov Identifier: | NCT00895271 History of Changes |
| Other Study ID Numbers: | 090133, 09-I-0133 |
| Study First Received: | May 7, 2009 |
| Last Updated: | November 26, 2014 |
| Health Authority: | United States: Federal Government |
Keywords provided by National Institutes of Health Clinical Center (CC):
|
Primary Immunodeficiency Immunodysregulation Skin Biopsy Induced Pluripotent Stem Cell (iPS) Lymphocyte |
Common Variable Immunodeficiency Severe Combined Immunodeficiency Healthy Volunteer HV |
Additional relevant MeSH terms:
|
Common Variable Immunodeficiency Immunologic Deficiency Syndromes Lymphohistiocytosis, Hemophagocytic Severe Combined Immunodeficiency DNA Repair-Deficiency Disorders Histiocytosis |
Histiocytosis, Non-Langerhans-Cell Immune System Diseases Infant, Newborn, Diseases Lymphatic Diseases Metabolic Diseases |
ClinicalTrials.gov processed this record on February 27, 2015